Straumann Holding Ltd header image

Straumann Holding Ltd

STMN

Equity

ISIN CH1175448666 / Valor 117544866

SIX Swiss Exchange (2026-09-03)
CHF 95.02-1.35%

Straumann Holding Ltd
UMushroom community rating:

star star star star star
4.50 2 votes No rating yet
NegativeNeutralPositive

About company

Straumann Holding Ltd is a Swiss dental company that specializes in manufacturing and distributing dental implants, prosthetics, and instruments for dental professionals worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (31.08.2026):

Straumann Holding Ltd — second quarter 2026: Straumann reported a strong Q2 2026 with revenue of CHF 707.0 million (organic growth 8.5%) and first‑half revenue of CHF 1,379.5 million (organic growth 7.8%). Profitability improved on a constant‑currency basis (core EBIT margin 26.9% at 2025 exchange rates), free cash flow rose to CHF 168.6 million (+49% YoY), and the company confirmed its upgraded full‑year 2026 outlook: high single‑digit organic revenue growth and core EBIT margin expansion of about 140–170 basis points (CER).

Revenue and growth

Q2 2026 revenue: CHF 707.0m (organic +8.5%; +5.9% in CHF YoY). H1 2026 revenue: CHF 1,379.5m (organic +7.8%; +2.3% in CHF YoY). Growth was broad‑based across regions and product lines.

Profitability

Core EBIT (H1 2026) improved to 26.9% at constant 2025 exchange rates (25.7% including currency effects). IFRS EBIT margin was 25.4%. Core net profit reached CHF 262.0m; core basic EPS CHF 1.64.

Cash flow & balance sheet

Free cash flow H1 2026: CHF 168.6m (+49% vs prior year), supported by higher operating cash flow and lower capex (CHF 74.1m vs CHF 113.0m prior). Cash and cash equivalents: CHF 381.0m; net cash position: CHF 34.7m; equity ratio: 58.6%.

Regional performance

EMEA and North America each delivered organic growth above 8% in Q2 2026. Asia Pacific grew 7.4% overall (ex‑China +25.0%). Latin America grew 11.8% organically, with Brazil and Hispanic markets strong contributors.

Key business drivers

Premium implantology led by iEXCEL drove customer conversions and market‑share gains; Neodent continued rapid expansion in the challenger segment. Digital solutions (notably SIRIOS X3 scanners and the cloud‑based Straumann AXS platform) showed strong adoption and are scaling the Group’s connected‑workflow ecosystem.

Operational efficiency & investments

Profitability benefited from manufacturing productivity, supply‑chain optimization and disciplined resource management. Capital investments continue (Shanghai campus, Curitiba expansion) but capex intensity declined versus prior periods after significant capacity build‑out.

Outlook & guidance

Straumann Holding Ltd confirms its updated 2026 guidance: expect high single‑digit organic revenue growth and core EBIT margin expansion of ~140–170 bps at constant 2025 exchange rates, with improvement distributed evenly across H1 and H2 (subject to usual risks and uncertainties).

Non‑core items

H1 2026 non‑core pre‑tax items include M&A amortization and contingent consideration changes (CHF 13.9m), legal case costs related to Align litigation (CHF 18.0m), a CHF 1.0m pension plan effect and tariff‑related refunds classified as other non‑recurring income. Core metrics exclude these items for comparability.

Summarized from source with an LLMView Source

Key figures

2.24%1Y
-29.0%3Y
-46.6%5Y

Performance

31.2%1Y
32.2%3Y
35.8%5Y

Volatility

Market cap

18724 M

Market cap (USD)

Daily traded volume (Shares)

433,642

Daily traded volume (Shares)

1 day high/low

115.85 / 114.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

2 votes
Performance:
starstarstarstarstar
4.50
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.75
Nature:
starstarstarstarstar
4.50
Aloïs Graber
Switzerland, 02 Nov 2025
star star star star star
Strong B2B business
Marc Roethlisberger
Switzerland, 17 Apr 2025
star star star star star
Hätte grundsätzlich Potential.

EQUITIES OF THE SAME SECTOR

Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203204
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.09%CHF 356.50
Alcon Inc.
Alcon Inc. Alcon Inc. Valor: 43249246
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.29%CHF 58.00
BACHEM HOLDING LTD
BACHEM HOLDING LTD BACHEM HOLDING LTD Valor: 117649372
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.28%CHF 78.50
Ypsomed Holding AG
Ypsomed Holding AG Ypsomed Holding AG Valor: 1939699
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.02%CHF 406.80
Medacta Group Ltd
Medacta Group Ltd Medacta Group Ltd Valor: 46852522
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.41%CHF 125.60
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%CHF 55.70
medmix Ltd
medmix Ltd medmix Ltd Valor: 112967710
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.67%CHF 8.99
DocMorris Ltd
DocMorris Ltd DocMorris Ltd Valor: 4261528
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.78%CHF 10.19
IVF HARTMANN Holding AG
IVF HARTMANN Holding AG IVF HARTMANN Holding AG Valor: 18762425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.44%CHF 126.50
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A. Valor: 2791431
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.81%CHF 12.38